27821288|t|Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen
27821288|a|Side population (SP) cells, a subset of enriched tumor initiating cells, have been demonstrated to have stem cell -like properties in multiple myeloma (MM) by us as well as other previous studies. A lack of agents targeting tumor initiating cells, however, represents a challenge in the treatment of MM. Previously, fenretinide, a well-tolerated vitamin A derivative, has been shown to exert effect on leukemic stem cells, but its actions against myeloma stem-like cells are still unknown. In this study, the effects of fenretinide on myeloma stem-like cells characteristic was comprehensively examined in SP and non-SP (MP) cells of NCI-H929 cell sorted by flow cytometry -based on Hoechst 33342 stain. We find that fenretinide is capable of eradicating MM SP and MP cells, but not normal bone marrow mononuclear cells (BMMCs) at physiologically achievable concentrations. Fenretinide alone exerted a selective cytotoxic effect on MM SP cells, as well as in combination with bortezomib and dexamethasone. In particular, SP cells were highly sensitive to fenretinide, and in combination with bortezomib and dexamethasone in colony formation and apoptosis assays. Accordingly, the apparent fenretinide -induced- apoptosis was linked to the rapid generation of reactive oxygen species (ROS). Therefore, we propose that fenretinide is a potent agent that targets tumor initiating cells and may be a promising therapeutic agent in MM treatment.
27821288	0	11	Fenretinide	T103	UMLS:C0060197
27821288	24	39	side population	T017	UMLS:C2936608
27821288	43	69	myeloma cell line NCI-H929	T017	UMLS:C0333843
27821288	102	113	antimyeloma	T033	UMLS:C0243095
27821288	119	155	bortezomib and dexamethasone regimen	T058	UMLS:C1879895
27821288	156	182	Side population (SP) cells	T017	UMLS:C2936608
27821288	205	227	tumor initiating cells	T017	UMLS:C1956421
27821288	260	269	stem cell	T017	UMLS:C0038250
27821288	290	306	multiple myeloma	T038	UMLS:C0026764
27821288	308	310	MM	T038	UMLS:C0026764
27821288	380	402	tumor initiating cells	T017	UMLS:C1956421
27821288	443	452	treatment	T058	UMLS:C0087111
27821288	456	458	MM	T038	UMLS:C0026764
27821288	472	483	fenretinide	T103	UMLS:C0060197
27821288	502	522	vitamin A derivative	T103	UMLS:C0042839
27821288	558	577	leukemic stem cells	T017	UMLS:C1517806
27821288	603	626	myeloma stem-like cells	T017	UMLS:C0333843
27821288	676	687	fenretinide	T103	UMLS:C0060197
27821288	691	714	myeloma stem-like cells	T017	UMLS:C0333843
27821288	762	764	SP	T017	UMLS:C2936608
27821288	769	786	non-SP (MP) cells	T017	UMLS:C0334227
27821288	790	803	NCI-H929 cell	T017	UMLS:C0333843
27821288	814	828	flow cytometry	T058	UMLS:C0016263
27821288	839	858	Hoechst 33342 stain	T103	UMLS:C0062907
27821288	873	884	fenretinide	T103	UMLS:C0060197
27821288	911	913	MM	T038	UMLS:C0026764
27821288	914	916	SP	T017	UMLS:C2936608
27821288	921	929	MP cells	T017	UMLS:C0334227
27821288	1030	1041	Fenretinide	T103	UMLS:C0060197
27821288	1088	1090	MM	T038	UMLS:C0026764
27821288	1091	1093	SP	T017	UMLS:C2936608
27821288	1132	1160	bortezomib and dexamethasone	T058	UMLS:C1879895
27821288	1177	1179	SP	T017	UMLS:C2936608
27821288	1211	1222	fenretinide	T103	UMLS:C0060197
27821288	1248	1276	bortezomib and dexamethasone	T058	UMLS:C1879895
27821288	1301	1310	apoptosis	T038	UMLS:C0162638
27821288	1311	1317	assays	T058	UMLS:C0005507
27821288	1345	1356	fenretinide	T103	UMLS:C0060197
27821288	1367	1376	apoptosis	T038	UMLS:C0162638
27821288	1473	1484	fenretinide	T103	UMLS:C0060197
27821288	1497	1502	agent	T103	UMLS:C1254351
27821288	1516	1538	tumor initiating cells	T017	UMLS:C1956421
27821288	1562	1579	therapeutic agent	T103	UMLS:C1611640
27821288	1583	1585	MM	T038	UMLS:C0026764
27821288	1586	1595	treatment	T058	UMLS:C0087111